- Home
- MDGL vs PEN Comparison
MDGL vs PEN Comparison
Compare MDGL & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | PEN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 12.6B |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MDGL | PEN |
|---|---|---|
| Price | $519.09 | $323.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 16 |
| Target Price | ★ $674.45 | $360.14 |
| AVG Volume (30 Days) | ★ 372.3K | 304.0K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | N/A | ★ 1.70 |
| Revenue | $180,133,000.00 | ★ $1,403,665,000.00 |
| Revenue This Year | $58.39 | $14.34 |
| Revenue Next Year | $48.55 | $13.71 |
| P/E Ratio | ★ N/A | $192.26 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $393.61 | $221.26 |
| 52 Week High | $615.00 | $362.41 |
Technical Indicators
Market Signals| Indicator | MDGL | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 55.40 |
| Support Level | $498.59 | $315.31 |
| Resistance Level | $545.13 | $329.67 |
| Average True Range (ATR) | 19.22 | 2.02 |
| MACD | 1.86 | -0.00 |
| Stochastic Oscillator | 76.90 | 46.34 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.